Safety of SGLT-2 inhibitors in patients with glycogen storage disease type Ib and their efficacy in treating disease-associated digestive symptoms and disorders

Key Points

• SGLT-2 inhibitors show favorable results for alleviating digestive symptoms.
• Key evidence indicates significant improvements in metabolic markers after treatment.
• Assessment of clinical data highlights the relationship between drug intervention and digestive health.
• Findings suggest that SGLT-2 inhibitors may be a valuable option, though further validation is necessary.